AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35575067 — intervention group
Group type: EXPERIMENTAL
Intervention: WP1066 at 1 mg/kg
Number of subjects: 8
Study 34233923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 124
Study 34233923 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 124
Study 34233923 — intervention group
Group type: COMPARATOR
Intervention: Hemodiafiltration and High-flux hemodialysis
Number of subjects: 124
Study 33554636 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide and hormone therapy
Number of subjects: 1509
Study 33554636 — intervention group
Group type: COMPARATOR
Intervention: Placebo and hormone therapy
Number of subjects: 1509
Study 32273184 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-Al
Number of subjects: 800
Study 32273184 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 800
Study 35227973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Orientation messages recorded in a non-family member's voice (10 min), reading a daily newspaper, wearing an eye patch at night
Number of subjects: 0
Study 35227973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Orientation messages recorded in a family member's voice, reading a daily newspaper, wearing an eye patch at night
Number of subjects: 0
Study 35227973 — intervention group
Group type: COMPARATOR
Intervention: Control group: Standard nursing care
Number of subjects: 0
Study 35051209 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-6500 (0.1% GRFT in a carrageenan gel)
Number of subjects: 13
Study 35051209 — intervention group
Group type: COMPARATOR
Intervention: PC-535 (matching CG placebo)
Number of subjects: 13
Study 32918114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with FVIII/FIX
Number of subjects: 53
Study 32918114 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy
Number of subjects: 53
Study 32918114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with FVIII/FIX in SHB
Number of subjects: 53
Study 32918114 — intervention group
Group type: COMPARATOR
Intervention: On-demand therapy and hepatitis B and C
Number of subjects: 53
Study 32918114 — intervention group
Group type: COMPARATOR
Intervention: Age, weight, and HIV positivity
Number of subjects: 53
Study 34957859 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 11
Study 34957859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 33665997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 15 mg/kg intravenous drops before operation incision at 10 min
Number of subjects: 34
Study 33665997 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 ml normal saline intravenous drops before operation incision at 10 min)
Number of subjects: 34
Study 35901201 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exertion (50 minutes of treadmill exercise in a heated room while wearing firefighter protective clothing)
Number of subjects: 24
Study 35901201 — intervention group
Group type: COMPARATOR
Intervention: Total sleep deprivation
Number of subjects: 24
Study 35901201 — intervention group
Group type: COMPARATOR
Intervention: Sleep disruption (three 60-minute awakenings)
Number of subjects: 24
Study 35901201 — intervention group
Group type: COMPARATOR
Intervention: Rested control
Number of subjects: 24
Study 34553603 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, and dexamethasone (Isa-Kd)
Number of subjects: 0
Study 34553603 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd) alone
Number of subjects: 0
Study 36267873 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT-PTSD) for 14 weeks
Number of subjects: 74
Study 36267873 — intervention group
Group type: COMPARATOR
Intervention: Sertraline for 14 weeks
Number of subjects: 74
Study 34516036 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Through Play (LTP) plus Culturally adapted Cognitive Behaviour Therapy (CaCBT)
Number of subjects: 0
Study 35953335 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ROM exercises (AE)
Number of subjects: 35
Study 35953335 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful activity (PA)
Number of subjects: 35
Study 33128939 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 65
Study 33128939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 65
Study 32127870 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep arm - AuraOnce™ laryngeal mask removed after attaining an end tidal minimum alveolar concentration of Isoflurane of 1.15%.
Number of subjects: 116
Study 32127870 — intervention group
Group type: COMPARATOR
Intervention: Awake arm - AuraOnce™ laryngeal mask removed on attaining an end tidal minimum alveolar concentration of Isoflurane of <0.5% and an appropriate response to command.
Number of subjects: 116
Study 36442217 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infant oral motor intervention for five minutes twice a day along with routine care (n=16)
Number of subjects: 32
Study 36442217 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n=16)
Number of subjects: 32
Study 33369019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory long-chain inulin consumption for two months
Number of subjects: 0
Study 33369019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32506744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (3 Hz)
Number of subjects: 45
Study 32506744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1 Hz)
Number of subjects: 45
Study 32506744 — intervention group
Group type: COMPARATOR
Intervention: SHAM rTMS
Number of subjects: 45
Study 34431240 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg) after overnight fast
Number of subjects: 24
Study 34431240 — intervention group
Group type: COMPARATOR
Intervention: Vonoprazan (20 mg) after high-fat breakfast
Number of subjects: 24
Study 33654204 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 717
Study 33654204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 32241699 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 72
Study 32241699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34403189 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care activities during COVID-19 pandemic
Number of subjects: 26
Study 34403189 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-building strategies
Number of subjects: 26
Study 34403189 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote consultations with health professionals
Number of subjects: 26
Study 32933335 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immunochemotherapy
Number of subjects: 0
Study 32933335 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-based immunochemotherapy
Number of subjects: 0
Study 35460410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using validated tools to detect signs and symptoms of medicine-induced deterioration every 8 weeks over 12 months
Number of subjects: 248
Study 35460410 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Residential Medication Management Review) provided by accredited pharmacists
Number of subjects: 248
Study 32039559 — intervention group
Group type: COMPARATOR
Intervention: CNI-based immunosuppressive regimen (tacrolimus)
Number of subjects: 43
Study 32039559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CNI plus costimulation blockade (belatacept) with intended CNI withdrawal
Number of subjects: 43
Study 33902678 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk enema
Number of subjects: 294
Study 33902678 — intervention group
Group type: COMPARATOR
Intervention: Saline enema
Number of subjects: 294
Study 33198679 — intervention group
Group type: COMPARATOR
Intervention: D&C
Number of subjects: 404
Study 33198679 — intervention group
Group type: COMPARATOR
Intervention: EVA
Number of subjects: 404
Study 33198679 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 404
Study 34984815 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin 1000 mg twice daily
Number of subjects: 215
Study 34984815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 33499719 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Attitudes about Childhood Vaccines (PACV) survey
Number of subjects: 1705
Study 33499719 — intervention group
Group type: COMPARATOR
Intervention: Placebo survey
Number of subjects: 1705
Study 32856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral culture from respiratory samples
Number of subjects: 100
Study 32856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion for IgM
Number of subjects: 100
Study 32856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion for IgG
Number of subjects: 100
Study 32856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of inflammatory cytokines and chemokines
Number of subjects: 100
Study 32856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 100
Study 34753654 — intervention group
Group type: COMPARATOR
Intervention: HFOV
Number of subjects: 58
Study 34753654 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV-VG
Number of subjects: 58
Study 33674671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin for neuroprotection
Number of subjects: 94
Study 33674671 — intervention group
Group type: COMPARATOR
Intervention: Control (no CP)
Number of subjects: 94
Study 33674671 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole transcriptome analysis
Number of subjects: 94
Study 35546457 — intervention group
Group type: EXPERIMENTAL
Intervention: Melaleuca alternifolia
Number of subjects: 160
Study 35546457 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 160
Study 35546457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 33389005 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for cosmetic reasons
Number of subjects: 183
Study 33389005 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for functional reasons
Number of subjects: 183
Study 33389005 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with dissatisfaction (Groups 2, 4, and 6)
Number of subjects: 183
Study 33389005 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation coverage rates
Number of subjects: 183
Study 35701994 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted THA (n = 45)
Number of subjects: 93
Study 35701994 — intervention group
Group type: COMPARATOR
Intervention: Conventional THA (n = 48)
Number of subjects: 93
Study 34180008 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 271
Study 35585718 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 402
Study 35585718 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine
Number of subjects: 402
Study 35585718 — intervention group
Group type: EXPERIMENTAL
Intervention: pregabalin
Number of subjects: 402
Study 35585718 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 402
Study 35585718 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 402
Study 32493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 264
Study 32493359 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 264
Study 32493359 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 264
Study 32493359 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 264
Study 35705234 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 108
Study 35705234 — intervention group
Group type: COMPARATOR
Intervention: Nontracker group
Number of subjects: 108
Study 35705234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 32119692 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming positions language
Number of subjects: 0
Study 32119692 — intervention group
Group type: COMPARATOR
Intervention: Priming interests language
Number of subjects: 0
Study 32119692 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of gain frames and visual aids during bargaining
Number of subjects: 0
Study 32119692 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of loss frames and pro-self language
Number of subjects: 0
Study 36496124 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Regional Analgesia (CRA)
Number of subjects: 76
Study 36496124 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (Control)
Number of subjects: 76
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 6144
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 6144
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential tamoxifen → letrozole
Number of subjects: 6144
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential letrozole → tamoxifen
Number of subjects: 6144
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen → letrozole
Number of subjects: 6144
Study 33159633 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole → tamoxifen
Number of subjects: 6144
Study 33159633 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 6144
Study 36195272 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 18
Study 36195272 — intervention group
Group type: COMPARATOR
Intervention: Control (average Danish diet)
Number of subjects: 18
Study 34193518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 34193518 — intervention group
Group type: COMPARATOR
Intervention: Standard care (immobilisation, analgesics, spinal orthoses)
Number of subjects: 0
Study 32700515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-containing NaF dentifrice
Number of subjects: 60
Study 32700515 — intervention group
Group type: COMPARATOR
Intervention: NaF control dentifrice
Number of subjects: 60
Study 33515378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid (AA) solution (0.005%) irrigated by a water pump
Number of subjects: 412
Study 33515378 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 412
Study 33295220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine infusion (0.5 mg/kg bolus at induction, 0.25 mg/kg/h during surgery)
Number of subjects: 48
Study 33295220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine infusion
Number of subjects: 48
Study 33295220 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 48
Study 32894239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training along with a combined physiotherapy program for six weeks.
Number of subjects: 50
Study 32894239 — intervention group
Group type: COMPARATOR
Intervention: Combined physiotherapy program for six weeks (Control group).
Number of subjects: 50
Study 34774810 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS+PLUS Intervention
Number of subjects: 49
Study 34774810 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Treatment-as-usual
Number of subjects: 49
Study 33180098 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 injection (1000 μg of cyanocobalamin)
Number of subjects: 20
Study 33180098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study 33180098 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 injection
Number of subjects: 20
Study 33180098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33180098 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 injection and Placebo
Number of subjects: 20
Study 32898855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serving fish sauce in a bowl with a spoon
Number of subjects: 0
Study 32898855 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a specially-designed spoon with a hole
Number of subjects: 0
Study 32898855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-oriented nudges
Number of subjects: 0
Study 32898855 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective-oriented nudges
Number of subjects: 0
Study 32898855 — intervention group
Group type: COMPARATOR
Intervention: Normal condition (fish sauce served in a bottle)
Number of subjects: 0
Study 35670659 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily titration of iGlarLixi (1 unit/day)
Number of subjects: 265
Study 35670659 — intervention group
Group type: COMPARATOR
Intervention: Weekly titration of iGlarLixi (2 or 4 units/week)
Number of subjects: 265
Study 33295063 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 84
Study 33295063 — intervention group
Group type: COMPARATOR
Intervention: Exercise Group (EG) with ≥50% exercise attendance
Number of subjects: 84
Study 33749539 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (6.4% maltodextrin = 1.6 g)
Number of subjects: 8
Study 33749539 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF mouth rinse (1.2% caffeine = 300 mg)
Number of subjects: 8
Study 33749539 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + CAF mouth rinse (6.4% + 1.2%)
Number of subjects: 8
Study 33749539 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (saccharin)
Number of subjects: 8
Study 33723344 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM THA stem
Number of subjects: 62
Study 33723344 — intervention group
Group type: COMPARATOR
Intervention: BM THA stem
Number of subjects: 62
Study 32310169 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-1204 (caprylic triglyceride)
Number of subjects: 413
Study 32310169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 33860732 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant (NZBC) powder (6 g/day for 7 days, with 138.6 mg anthocyanins)
Number of subjects: 14
Study 32838616 — intervention group
Group type: EXPERIMENTAL
Intervention: OD-evening 80 mg aspirin
Number of subjects: 22
Study 32838616 — intervention group
Group type: EXPERIMENTAL
Intervention: BID 40 mg aspirin
Number of subjects: 22
Study 32838616 — intervention group
Group type: COMPARATOR
Intervention: OD-morning 80 mg aspirin
Number of subjects: 22
Study 34995804 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading with individualized supplemental insulin
Number of subjects: 63
Study 34995804 — intervention group
Group type: COMPARATOR
Intervention: Routine management (Control group)
Number of subjects: 63
Study 33527072 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital group intervention via Zoom (n = 64)
Number of subjects: 82
Study 33527072 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 18)
Number of subjects: 82
Study 35751892 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus dapagliflozin (0.6 mg liraglutide and 5 mg dapagliflozin once a day)
Number of subjects: 125
Study 35751892 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (0.6 mg)
Number of subjects: 125
Study 32340150 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-Enriched Diet (AED)
Number of subjects: 128
Study 32340150 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric Nut-Free Diet (NFD)
Number of subjects: 128
Study 32007178 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including muscle strengthening and proprioceptive re-education exercises
Number of subjects: 8
Study 34773355 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine contractile activity during TOLAC
Number of subjects: 194
Study 34773355 — intervention group
Group type: COMPARATOR
Intervention: Cervical ripening with a Foley catheter
Number of subjects: 194
Study 34773355 — intervention group
Group type: COMPARATOR
Intervention: Cervical dilatation <3 cm at admission
Number of subjects: 194
Study 34773355 — intervention group
Group type: EXPERIMENTAL
Intervention: Total uterine rupture incidence
Number of subjects: 194
Study 32598387 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) 4 mg for 24 days followed by 4 days of placebo
Number of subjects: 858
Study 32598387 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel (DSG) 0.075 mg per day continuously
Number of subjects: 858
Study 35870575 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reduction to very low nicotine content (VLNC) cigarettes
Number of subjects: 1250
Study 35870575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction to very low nicotine content (VLNC) cigarettes
Number of subjects: 1250
Study 35870575 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine research cigarettes (control)
Number of subjects: 1250
Study 32165263 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week processing speed and attention (PS/A)‐targeted intervention
Number of subjects: 84
Study 32165263 — intervention group
Group type: COMPARATOR
Intervention: Active control without PS/A
Number of subjects: 84
Study 35679254 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 24
Study 35679254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 33241607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for blood pressure reduction
Number of subjects: 0
Study 33241607 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention to treat substance use disorders
Number of subjects: 0
Study 34958381 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling focused on pain management
Number of subjects: 0
Study 33920981 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical training, nutritional, and social support intervention over 24 weeks
Number of subjects: 80
Study 32664934 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based partner notification through a mobile health (mHealth) service application (app)
Number of subjects: 6172